Aging Population And Value-Based Care Will Expand Opportunities

Key Takeaways

• Strategic focus on higher-value contracts, data analytics, and top-performing partners sets the stage for improved margins and predictable, higher-quality revenue.
  
• agilon's value-based care platform, enabled by AI and physician partnerships, is well-positioned for durable growth and market share gains as the industry shifts.
  
• Mounting regulatory hurdles, operational inefficiencies, and intensifying competitive pressures threaten agilon health's revenue stability, margin growth, and long-term market position.

Catalysts

Provides healthcare services for seniors through primary care physicians in the communities of the United States.

• Analysts broadly agree that reducing Medicare Part D exposure and focusing on higher-value contracts will moderate volatility, but this catalyst is understated; given accelerating industry tailwinds and stronger-than-expected payer appetite for quality incentives, agilon could see a sharp improvement in net margins and more predictable revenue streams by 2026, particularly as payers allocate more dollars to proven quality outperformers.
  
• While consensus suggests that agilon's measured approach to 2025 Medicare Advantage membership constrains near-term top-line growth, the enhanced engagement with top-performing partners and selective market participation now underway could drive higher revenue per member and structural margin expansion post-2026 as industry premium rates normalize and competitive pressures ease.
  
• agilon's investments in advanced data analytics and AI-driven care management are beginning to deliver earlier identification and intervention for high-cost chronic conditions, which positions the company to outperform in cost containment and risk adjustment, yielding a step-change in medical margin and earnings in the medium term.
  
• As the aging U.S. population rapidly expands the pool of complex, high-need seniors, agilon's proven track record of enabling primary care physicians and scaling in new geographies provides a durable growth engine that could deliver accelerated top-line growth and market share gains well above broader industry projections starting in 2026.
  
• The ongoing shift to value-based care and regulatory support for these payment models is intensifying payer-provider convergence and industry consolidation, making agilon's platform increasingly strategic for both physicians and payers; this amplifies the company's competitive advantages and boosts the likelihood of premium contracting, higher recurring revenues, and improved long-term profitability.

agilon health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on agilon health compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming agilon health's revenue will grow by 8.9% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -6.4% today to 1.9% in 3 years time.
• The bullish analysts expect earnings to reach $145.5 million (and earnings per share of $8.5) by about July 2029, up from -$373.5 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-73.8 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 17.2x on those 2029 earnings, up from -4.8x today. This future PE is lower than the current PE for the US Healthcare industry at 25.4x.
• The bullish analysts expect the number of shares outstanding to grow by 0.64% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

• Increased regulatory scrutiny and changes to Medicare Advantage reimbursement, combined with recent underperformance in risk adjustment and lower-than-expected risk scores for 2024 and 2025, have already reduced agilon health's revenue, introducing further uncertainty and potential margin pressures in future periods.
  
• Agilon health's difficulty in scaling profitably and the company's decision to withdraw 2025 guidance, as well as underwhelming outcomes from new clinical initiatives, point to ongoing challenges in controlling SG&A expenses and achieving sustainable earnings growth.
  
• Macroeconomic factors such as rising inflation, increasing operational costs, and potentially more expensive access to capital may further depress net margins, especially as agilon health's adjusted EBITDA moved deeply negative compared to the prior year period.
  
• The company's concentrated dependence on a limited number of large payer partners increases its vulnerability to contract renegotiations, which could lead to earnings volatility and restrict top-line revenue growth-especially as approximately 50% of membership is up for renewal and payers seek improved economics.
  
• Industry-wide shifts toward digital disruption and new competitors leveraging advanced technology risk outpacing agilon health's innovation, which, combined with rising patient expectations and ongoing consolidation among payors and providers, may result in patient attrition, compressed pricing power, lower market share, and diminished revenue opportunities.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for agilon health is $120.0, which represents up to two standard deviations above the consensus price target of $66.64. This valuation is based on what can be assumed as the expectations of agilon health's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $120.0, and the most bearish reporting a price target of just $22.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $7.5 billion, earnings will come to $145.5 million, and it would be trading on a PE ratio of 17.2x, assuming you use a discount rate of 7.1%.
• Given the current share price of $107.47, the analyst price target of $120.0 is 10.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.